Search Results - "Lesnock, J"

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study by Lesnock, J L, Darcy, K M, Tian, C, DeLoia, J A, Thrall, M M, Zahn, C, Armstrong, D K, Birrer, M J, Krivak, T C

“…Background: Breast cancer 1, early onset ( BRCA1 ) is a tumour-suppressor gene associated with familial epithelial ovarian cancer (EOC). Reduced BRCA1…”
Get full text

Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? – A single-institution study by Pifer, P.M., Bhargava, R., Patel, A.K., Ling, D.C., Vargo, J.A., Orr, B.C., Sukumvanich, P., Courtney-Brooks, M.B., Boisen, M.M., Berger, J.L., Taylor, S., Olawaiye, A.B., Comerci, J.T., Lesnock, J.L., Edwards, R.P., Beriwal, S.

“…A pooled analysis of PORTEC-1 & 2 identified substantial lymphovascular space invasion (LVSI) in 4.8% of patients, which predicted for pelvic recurrence,…”
Get full text

Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer by Orellana, T.J., Kim, H., Beriwal, S., Bhargava, R., Berger, J., Buckanovich, R.J., Coffman, L.G., Courtney-Brooks, M., Mahdi, H., Olawaiye, A.B., Sukumvanich, P., Taylor, S.E., Smith, K.J., Lesnock, J.L.

“…Tumor molecular analyses in endometrial cancer (EC) includes 4 distinct subtypes: (1) POLE-mutated, (2) mismatch repair protein (MMR) deficient, (3) p53…”
Get full text

The role of adjuvant treatment for early-stage uterine clear cell carcinomas by Orellana, T.J., Garrett, A.A., Soong, T.R., Rives, T., Courtney-Brooks, M., Taylor, S.E., Lesnock, J., Berger, J., Boisen, M., Coffman, L., Buckanovich, R., Mahdi, H., Comerci, J.C., Beriwal, S., Sukumvanich, P., Edwards, R.P., Bhargava, R., Olawaiye, A.B.

“…Uterine clear cell carcinoma is a rare and aggressive subtype of endometrial carcinoma. Prospective clinical trials have not been feasible for this rare tumor,…”
Get full text

Is Substantial Lymphovascular Space Invasion Prognostic for Clinical Outcomes in Type II Endometrial Cancer? by Jaishankar, S., Pifer, P.M., Bhargava, R., Keller, A., Musunuru, H.B., Patel, A.K., Sukumvanich, P., Boisen, M., Berger, J.L., Taylor, S., Courtney-Brooks, M., Olawaiye, A., Lesnock, J., Edwards, R., Vargo, J.A., Beriwal, S.

“…Substantial lymphovascular space invasion (LVSI) compared with none or focal LVSI is predictive of lymph node involvement and worse clinical outcomes in…”
Get full text

Palliative care education in gynecologic oncology: A survey of the fellows by Lesnock, J.L, Arnold, R.M, Meyn, L.A, Buss, M.K, Quimper, M, Krivak, T.C, Edwards, R.P, Chang, J.C

“…Abstract Introduction Gynecologic oncologists regularly care for patients at the end of life, yet little is known about their training or preparedness to deal…”
Get full text

Neoadjuvant chemotherapy is less costly than primary debulking surgery for treatment of advanced stage ovarian cancer in patients ≥ 65 years old by Farris, C, Lesnock, J, Krivak, T

Get full text

Cost comparison of primary debulking surgery to neoadjuvant chemo- therapy for treatment of advanced stage ovarian cancer in patients ≥ 65 years old by Farris, C, Lesnock, J, Krivak, T

Get full text

Intensity modulated radiation therapy improves quality of life compared to four field radiation therapy for upfront treatment of locally advanced cervical cancer: A cost-effectiveness analysis by Lesnock, J, Farris, C, Beriwal, S, Krivak, T

Get full text

Abstract 10: Comparison of outcomes in patients undergoing rectosigmoid resection: End colostomy versus reanastomosis by Lesnock, J, Beriwal, S, Krivak, T, Olawaiye, A, Lin, J, Sukumvanich, P

Get full text

Occult uterine cancer in patients undergoing laparoscopic hysterectomy with morcellation: Implications for surveillance for disease recurrence and outcomes by Lesnock, J, Edwards, R, Richard, S, Zorn, K, Sukumvanich, P, Krivak, T

Get full text

Comparison of outcomes in patients undergoing rectosigmoid resection: End colostomy versus reanastomosis by Lesnock, J, Beriwal, S, Krivak, T, Olawaiye, A, Lin, J, Sukumvanich, P

Get full text

Occult uterine cancer in patients undergoing laparoscopic hysterectomy with morcellation by Rowland, M, Lesnock, J, Edwards, R, Richard, S, Zorn, K, Sukumvanich, P, Krivak, T

Get full text

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced ovarian cancer by Lesnock, J, Farris, C, Krivak, T, Smith, K, Markman, M

Get full text

CA125 Surveillance and Second-line Intraperitoneal Platinum-based Therapy Increases Second Line Progression-free Survival for Epithelial Ovarian Cancer by Boisen, M, Lesnock, J, McBee, W, Richard, S, Kelley, J, Zorn, K, Krivak, T, Edwards, R

Get full text

Impact of Postoperative Treatment on Stage IIIC Endometrial Cancer: A Comparison of Single Modality to Multimodality Therapy by Hansen, K, Lin, J, Beriwal, S, Lesnock, J, Sukumvanich, P, Richard, S, Olawaiye, A, Kelley, J, Zorn, K, Krivak, T

Get full text

The risk for omental metastases and the impact on overall survival in patients with uterine papillary serous and clear cell endometrial cancer by Boisen, M, Lesnock, J, Sukumvanich, P, Beriwal, S, Austin, R, Kelley, J, Zorn, K, Krivak, T, Olawaiye, A

Get full text

CA125 surveillance and second-line intraperitoneal platinum-based therapy increases second line progression-free survival for epithelial ovarian cancer by Boisen, M, Lesnock, J, McBee, W, Richard, S, Kelley, J, Zorn, K, Krivak, T, Edwards, R

Get full text

Chemotherapy response and survival in serous ovarian cancer patients with BRCA mutations by Chan, J, Kiet, T, Chen, L, Ruskin, R, Sherman, A, Lesnock, J, Monk, B, Kapp, D, Krivak, T

Get full text

Germline versus Somatic BRCA mutations: Analysis of the cancer genome atlas project in patients with advanced stage serous epithelial ovarian cancer by Lesnock, J, Krivak, T, Kiet, T, Sherman, A, Monk, B, Ruskin, R, Kapp, D, Chen, L, Chan, J

Get full text